Praxis Precision Medicines, Inc. , a clinical-stage biopharmaceutical company focused on translating genetic insights into therapies for central nervous system (CNS) disorders involving neuronal excitation-inhibition imbalance, today announced that on May 1, 2025, its Board of Directors' Compensation Committee granted restricted stock unit awards totaling 3,688 shares of its common stock to five new non-executive employees. These grants were made under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the "2024 Inducement Plan"). The restricted stock units were awarded as inducements material to the employees' decision to join Praxis, in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2024 Inducement Plan is designed exclusively for granting equity awards to individuals who are not current employees of Praxis, or who have had a bona fide period of non-employment, as an inducement to join the company, in line with Nasdaq Listing Rule 5635(c)(4).

Source: https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-inc-announces-inducement-grants-6